Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results for CAN10 were presented, pre-clinical data from a new IL1-RAP ADC were presented, and TRIFOUR was fully recruited, with a first ORR readout expected by mid-2025.
LÄS MER
